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Abstract 
Uterine leiomyosarcoma is a rare malignancy and carries a poorer prognosis when compared 
to endometrial carcinoma. It has been observed to metastasize to all the major organs. It 
presents with symptoms of abdominal distension, vaginal bleeding and may pass unnoticed 
until an advanced stage in patients with leiomyomas. Surgery is a viable option in patients 
with disease limited to the uterus, but metastasis to the heart may require surgery to prevent 
acute and catastrophic complications. The case described here involves  metastasis to the 
tricuspid valve, which caused severe tricuspid regurgitation in the setting of acute pulmonary 
embolism. Surgical resection restored cardiac function and stabilized the patient. This case 
illustrates a rare site of metastasis of leiomyosarcoma which required immediate intervention 
and resulted in a favorable outcome. 
Introduction 
Leiomyosarcoma is a malignancy of the soft tissue and accounts for 5–10% of soft tissue 
sarcomas [1]. Leiomyosarcomas are histologically similar, occur in varied locations, with the 
retroperitoneum being the most common site, and are spread by hematogenous route [2]. 
Uterine leiomyosarcomas are more aggressive and carry a poor prognosis irrespective of the 
stage of presentation [3]. They may be present in the uterus with leiomyomas, and both  
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tumors may express the estrogen receptor (ER) and the progesterone receptor (PR) [4]. The 
presence of 2 out of the 3 Stanford criteria, namely: prominent cellular atypia, areas of tumor 
necrosis and abundant mitoses has been correlated with a >10% risk of metastasis [5]. 
Uterine leiomyosarcomas have been known to metastasize to distant organs. They often 
present  as  vaginal  bleeding  and  may  be  detected  by  ultrasound  imaging  during  initial 
workup. The incidence of leiomyosarcoma in African-American woman is approximately 2-
fold higher than in Caucasian women [6]. Tamoxifen usage and pelvic radiation may increase 
the risk of development of uterine sarcoma [7–9]. The presence of symptoms such as an 
enlarged  uterus,  vaginal  bleeding,  abdominal  distension,  urinary  frequency,  etc.,  in  a 
postmenopausal woman with a prior history of leiomyomas should raise the suspicion of 
leiomyosarcoma. 
Uterine leiomyosarcomas have been known to spread to distant sites including the lung, 
abdomen, brain, breast, bone, skin, pancreas and kidney [10–17]. Brain metastasis has been 
rarely observed and peritoneal sarcomatosis has been occasionally documented [16, 18]. It 
is rare to detect an ER- and PR-positive mass actively growing on a heart valve. This case 
highlights the unusual presentation of uterine leiomyosarcoma as a mass attached to the 
tricuspid valve (TV). The location of the mass may contribute to hemodynamic instability 
and surgical intervention may be required immediately after presentation. 
Case Summary 
The patient is a 49-year-old woman with a past medical history significant for uterine 
fibroids and menorrhagia who presented with a complaint of heavy vaginal bleeding over 
the  previous  8  days,  progressive  weakness,  lightheadedness,  palpitations,  dyspnea  on 
exertion and lower abdominal pain. She denied chest pain, cough, hemoptysis, fever and sick 
contacts. Her uterine fibroids were treated in the past by blood transfusion and bilateral 
uterine artery and left ovarian artery embolization. She was treated for tuberculosis and was 
hepatitis C positive. She was not allergic to any medications and denied smoking tobacco, 
consuming alcohol or using intravenous drugs. She was noted to have a hemoglobin level of 
5.1 g/dl and received 5 units of packed red blood cells and levonorgestrel. Her shortness of 
breath improved marginally but she continued to have tachycardia. She was noted to have 
left  lower  extremity  swelling  which the patient  admitted  had  started  4–5  days  prior  to 
admission. 
A lower extremity Doppler ultrasound revealed extensive deep venous thrombosis and 
she  was  started  on  systemic  anticoagulation  with  dalteparin.  Her  chest  X-ray  revealed 
multiple bilateral pulmonary modules (fig. 1a, b). A chest CT showed saddle embolus and 
multiple bilateral pulmonary emboli with evidence of right heart strain. Multiple bilateral 
pulmonary nodules suspicious for metastatic disease and a moderate right-sided pleural 
effusion  and  a  trace  left-sided  pleural  effusion  were  also  noted  (fig.  2).  Her  physical 
examination was pertinent for tachycardia, normal breath sounds, distended abdomen with 
tenderness  to palpation  in the  lower quadrants (uterus  was  palpable) and  bilateral calf 
muscle swelling with tenderness. She underwent placement of an inferior vena cava filter 
and an endometrial biopsy. However, the next day morning the patient was noted to become 
severely  hypoxemic  with  an  altered  mental  state.  She  was  intubated  and  started  on 
vasopressors for shock. 
Due to persistent hypoxemia and hypotension she was taken to the operating room for 
thrombectomy. Intraoperative transesophageal echocardiography revealed  an underfilled 
left ventricle with interventricular septum flattening, massively dilated right atrium and an  
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extremely dilated right ventricle with reduced function. It also showed a mild-to-moderate 
pulmonary artery (PA) dilatation with a large mass in the right PA (possibly thrombus) and a 
severe tricuspid regurgitation with a large pedunculated, very mobile mass attached to the 
TV leaflets that moved from the right atrium to the right ventricle during the cardiac cycle 
(fig. 3). Intraoperatively, a large thrombus at the bifurcation of the PA which was extending 
into the PA branches was removed. The right atrium and the right ventricle were found to be 
devoid of any clots, but a worm-like mass attached to the anterior TV leaflet was identified 
and removed. Also a left lower lobe wedge resection was performed on a peripheral nodule 
and the right pleural effusion was drained. 
The patient continued to require a maximal dose of vasopressors and had to be main-
tained on extracorporal membrane oxygenation and renal replacement therapy. She was 
successfully extubated on postoperative day 6 and was transferred to the medical floor. 
Histology of the mass attached to the TV and the pulmonary nodule revealed spindle cells 
with  marked  nuclear  atypia,  frequent  mitoses,  extensive  necrosis  and  vascular  invasion 
consistent with leiomyosarcoma (fig. 4a). Immunohistochemistry was positive for smooth 
muscle actin (SMA), desmin, ER, PR and cyclin-dependent kinase inhibitor 2A (p16) (fig. 4b–
f).  It  was  negative  for  myogenin,  myogenic  differentiation  1  (myoD1)  and  cytokeratins 
(AE1/3). 
These findings support a diagnosis of leiomyosarcoma and likely represent metastasis 
from the uterus. The pleural fluid showed rare, isolated highly atypical cells of uncertain 
origin and scattered mesothelial cells. The endometrial biopsy revealed an early secretory 
endometrium. It is likely that this patient suffered from a massive pulmonary embolism due 
to a combination of a predisposed state of hypercoagulation due to malignancy and due to 
the possible obstructive nature of the mass on the TV. These findings suggest that uterine 
leiomyosarcoma may manifest itself as a mass on the heart valves, and early identification 
may help prevent life-threatening complications. 
Discussion 
Uterine leiomyosarcoma is a rare malignancy and comprises about 1% of uterine malig-
nancies,  with  an  annual  incidence  of  0.64/100,000  women  [19].  The  histopathological 
diagnosis  is  often  made  after  hysterectomy  as  endometrial  biopsies  or  dilatation  and 
curettage  may  not  yield  adequate  tissue  [20].  These  tumors  are  thought  to  arise  inde-
pendently and less than 5% of them arise from transformation of preexisting leiomyoma 
[21].  They  differ  from  leiomyomas  and  smooth  muscle  tumors  of  uncertain  malignant 
potential (STUMP) by the presence of atypia, mitoses and tumor necrosis [22]. These tumors 
often present in the fifth decade of life, usually as a pelvic mass with vaginal bleeding [23]. 
On CT and MRI imaging they may present as submucosal, intramural or subserosal masses 
which are heterogeneously enhancing with hemorrhage or calcifications [24, 25]. 
Definitively differentiating the radiological appearance of leiomyosarcomas from leio-
myomas  has  not  been  successful  and  histopathological  diagnosis  continues  to  be  the 
standard. The size and rapidity of growth may indicate malignancy but are not considered 
reliable indicators [26]. There is a low propensity for pelvic node involvement, but CT has 
been the most common imaging modality for investigating the presence and extent of extra-
uterine disease and distant metastasis [27]. Imaging by ultrasound may reveal increased 
vascularity indicative of malignancy [28]. Further investigation is required for FDG-PET to 
be established as an imaging modality for leiomyosarcomas [29].  
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The stage of the disease, mitotic count and tumor grade have been shown to be signifi-
cant factors to help determine the prognosis [23]. Hysterectomy has been the main stay of 
treatment  with  preservation  of  the  ovaries,  but  pelvic  lymphadenectomy  has  not  been 
advocated due to the low involvement of pelvic lymph nodes [23, 30]. Surgical reduction has 
been advocated in patients with localized single foci [31]. Doxorubicin had been the agent of 
choice  until  a  combination  of  gemcitabine  and  docetaxel  was  found  to  have  an  overall 
response rate of 53% in patients with advanced unresectable uterine leiomyosarcoma [32]. 
Trabectedin has been approved for use in Europe and is being currently investigated in 
combination with doxorubicin [33, 34]. Hormonal agents such as megestrol, medroxyproges-
terone and aromatase inhibitors are being investigated, but the increased risk of side effects 
like venous thromboembolism and osteoporosis are being recognized as impediments to 
their use [35, 36]. Radiotherapy has been shown to help improve pelvic control, but there is 
no evidence for similar benefit for distant metastasis [37]. 
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Fig. 1. a PA view of chest X-ray showing numerous pulmonary nodules. b Lateral view of chest X-ray 
showing pulmonary nodules. 
 
 
 
Fig. 2. Chest CT with contrast showing pulmonary nodules and a moderate right-sided pleural effusion. 
 
  
Case Rep Oncol 2013;6:119–126 
DOI: 10.1159/000346935 
 
© 2013 S. Karger AG, Basel 
www.karger.com/cro 
Marak et al.: Uterine Leiomyosarcoma Manifesting as a Tricuspid Valve Mass   
 
125 
 
Fig. 3. Transesophageal echocardiogram showing a large pedunculated mass attached to the TV. 
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Fig. 4.  a  Hematoxylin  and  eosin  staining  showing  spindle  cells  with  nuclear  atypia  on  the  right  and 
necrosis on the left side. b Immunostaining for SMA of the mass resected from the TV showing myofibro-
blasts.  c  Immunostaining  for  desmin  of  the  mass  resected  from  the  TV  showing  myofibroblasts  with 
smooth muscle differentiation. d Immunostaining for ER of the mass resected from the TV indicating its 
likely uterine origin. e Immunostaining for PR of the mass  resected from the  TV indicating its  likely 
uterine origin. f Immunostaining for cyclin-dependent kinase inhibitor 2A (p16) of the mass resected from 
the TV which helps distinguish it from leiomyoma. 
 